Comparative Pharmacology
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 15 IN PLASTIC CONTAINER.
ISMOTIC vs MANNITOL 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolality, thereby drawing water from extravascular spaces into the plasma and reducing intracranial pressure. It also increases renal tubular osmotic pressure, inhibiting water reabsorption and promoting diuresis.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Intravenous: 50-100 g (1-2 g/kg) as a 15-25% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV every 4-6 hours. For oliguric acute kidney injury: test dose of 0.2 g/kg IV over 3-5 minutes; if urine output >50 mL/hr, administer 50-100 g as 15-20% solution over 2-6 hours.
None Documented
None Documented
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life approximately 0.5–1 hour in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Renal: 90-95% unchanged; biliary/fecal: <5%
Renal: >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<2%).
Category C
Category A/B
Osmotic Diuretic
Osmotic Diuretic